DIVIS LABORATORIES
Back to Balance Sheet
|
DIVIS LABORATORIES Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹2,248 Cr | ₹1,755 Cr | ₹1,539 Cr | ₹2,454 Cr | ₹1,728 Cr |
What is the latest Total Current Liabilities ratio of DIVIS LABORATORIES ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹2,248 Cr |
| Mar2024 | ₹1,755 Cr |
| Mar2023 | ₹1,539 Cr |
| Mar2022 | ₹2,454 Cr |
| Mar2021 | ₹1,728 Cr |
How is Total Current Liabilities of DIVIS LABORATORIES Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹2,248 Cr | 28.09 | |
| Mar2024 | ₹1,755 Cr | 14.04 | |
| Mar2023 | ₹1,539 Cr | -37.30 | |
| Mar2022 | ₹2,454 Cr | 42.01 | |
| Mar2021 | ₹1,728 Cr | - | |
Compare Total Current Liabilities of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹170,257.2 Cr | 1.9% | 5.9% | 12.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹417,028.0 Cr | 0.3% | 9% | 8.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹146,801.0 Cr | 0.6% | 9.5% | 45% | Stock Analytics | |
| CIPLA | ₹108,861.0 Cr | 1.6% | 1.8% | -7.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,435.0 Cr | -1.5% | 5.7% | 14.5% | Stock Analytics | |
| MANKIND PHARMA | ₹92,784.1 Cr | 9.9% | 5.8% | -2% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | 1.9% |
5.9% |
12.6% |
| SENSEX | -1.8% |
-1.6% |
7.3% |
You may also like the below Video Courses